Five year follow up data from the Phase III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial were reported at annual meeting of the American Society of Haematology (ASH). 

The VISTA trial assessed overall survival (OS) after treatment with bortezomib in combination with melphalan and prednisone (VcMP) versus melphalan and prednisone (MP) alone, in patients with previously untreated multiple myeloma (MM) -  see NELM abstract for trial details.

The updated results showed:

- After a median follow-up of 60.1 months, median OS was 56.4 months in the VcMP arm compared to 43.1 months in the MP arm (HR 0.695, p=0.0004), reflecting a 13.3-month OS advantage.

- Among patients who received subsequent therapies, OS was statistically significantly longer in patients who received VcMP upfront compared to those who received MP (median 55.7 vs. 46.4 months; HR 0.745, p=0.0162).

- Time to next treatment (median 27.0 vs. 19.2 months; HR 0.557, p<0.0001) and treatment-free interval (median 16.6 vs. 8.3 months, HR 0.573, p<0.0001) were longer with VcMP versus MP.

- The exposure-adjusted incidence rate of 1.66 secondary primary malignancies per 100-patient-years for VcMP, and 1.30 SPM for MP alone .